Back to top
more

Pfizer (PFE)

(Real Time Quote from BATS)

$28.87 USD

28.87
12,948,956

-0.22 (-0.76%)

Updated Sep 30, 2024 03:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Should You Invest in the Vanguard Health Care ETF (VHT)?

by Zacks Equity Research

Sector ETF report for VHT

Pfizer (PFE) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, Pfizer (PFE) closed at $49.03, marking a +0.16% move from the previous day.

Pfizer (PFE) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sweta Killa headshot

Healthcare ETFs in Focus Ahead of Q1 Earnings

by Sweta Killa

The healthcare sector has gained some momentum lately on investors' rush to safety in a volatile stock market. The sector is non-cyclical in nature, which in turn, is providing a cushion to the portfolio.

Novavax (NVAX) Starts COVID-19 Booster Study in Adolescents

by Zacks Equity Research

Novavax's (NVAX) begins administering a third/booster dose of its COVID-19 vaccine in adolescents aged between 12 years and 17 years in a pivotal late-stage study.

Novavax (NVAX) Posts Upbeat Data on COVID/Flu Combo Jab Study

by Zacks Equity Research

Results from Novavax's (NVAX) phase I/II study, which is evaluating a combination of its COVID-19 vaccine and the seasonal influenza vaccine candidate, demonstrate the combo vaccine's feasibility.

Pfizer (PFE) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

In the latest trading session, Pfizer (PFE) closed at $49.75, marking a -0.86% move from the previous day.

Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock

by Zacks Equity Research

Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Moderna (MRNA) Posts Upbeat Data on Bivalent COVID Booster Jab

by Zacks Equity Research

Moderna's (MRNA) bivalent COVID booster candidate creates superior neutralizing antibodies compared to its currently authorized COVID vaccine mRNA-1273's booster dose against all variants of concern.

Exelixis (EXEL) Outperforms Industry YTD: What Lies Ahead?

by Zacks Equity Research

Exelixis (EXEL) gains 25% in the year so far on strong performance of Cabometyx and encouraging pipeline progress.

Pfizer (PFE), BioNTech (BNTX) COVID Booster Effective in Young Kids

by Zacks Equity Research

A third dose of Pfizer (PFE) and partner BioNTech's (BNTX) COVID-19 vaccine achieves a significant immune response against the Omicron variant in children aged between 5 years and 11 years.

Merck's (MRK) Pneumococcal Jab Gets FDA's Breakthrough Tag

by Zacks Equity Research

The FDA grants Breakthrough Therapy designation to Merck's (MRK) vaccine candidate, V116, for preventing invasive pneumococcal disease and pneumococcal pneumonia in adults.

Novavax (NVAX) COVID Jab Gets Nod for Use in Switzerland

by Zacks Equity Research

Novavax's (NVAX) Nuvaxovid is the first protein COVID-19 vaccine authorized for use in Switzerland. The stock price rises following the announcement.

Halozyme (HALO) to Acquire Antares for Auto Injector Platform

by Zacks Equity Research

Halozyme (HALO) is set to acquire Antares for $960 million by June. The acquisition will add Antares' auto injector platform to Halozyme's portfolio and complement its promising ENHANZE technology.

The Zacks Analyst Blog Highlights Pfizer, Charles Schwab, Vale, Citigroup, and Palo Alto Networks

by Zacks Equity Research

Pfizer, Charles Schwab, Vale, Citigroup, and Palo Alto Networks are part of the Top Analyst Blog.

Neena Mishra headshot

Healthcare ETFs Outperform Amid Rising Uncertainties

by Neena Mishra

Investors are seeking refuge in healthcare stocks as inflation and rates rise

Sheraz Mian headshot

Top Stock Reports for Pfizer, Charles Schwab & Vale

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Pfizer Inc. (PFE), The Charles Schwab Corporation (SCHW), and Vale S.A. (VALE).

Glaxo (GSK) to Buy Sierra for $1.9B, Add Hematology Drug

by Zacks Equity Research

The acquisition of Sierra Oncology (SRRA) will add late-stage oncology pipeline candidate, momelotinib to Glaxo's (GSK) hematology pipeline.

Ocugen (OCGN) Stock Down as FDA Puts Hold on Covaxin Study

by Zacks Equity Research

Ocugen (OCGN) is conducting the OCU-002 study to support its BLA for the approval of Covaxin in the United States. The FDA places a clinical hold on this study.

    FDA Finds Deficiencies in Myovant (MYOV), Pfizer's Myfembree sNDA

    by Zacks Equity Research

    Though the FDA identified deficiencies in Myovant's (MYOV) Myfembree sNDA for managing endometriosis-associated pain, a final decision on the application is yet to be communicated.

    Is Principal U.S. MegaCap ETF (USMC) a Strong ETF Right Now?

    by Zacks Equity Research

    Smart Beta ETF report for USMC

    Is Global X SuperDividend U.S. ETF (DIV) a Strong ETF Right Now?

    by Zacks Equity Research

    Smart Beta ETF report for DIV

    Pfizer (PFE) to Boost RSV Portfolio With ReViral Acquisition

    by Zacks Equity Research

    Pfizer (PFE) inks an agreement to acquire ReViral for up to $525 million, which will add the latter's respiratory syncytial virus therapeutic candidates to its portfolio.

    Centennial Resource Development and ShotSpotter have been highlighted as Zacks Bull and Bear of the Day

    by Zacks Equity Research

    Centennial Resource Development and ShotSpotter are part of Zacks Bull and Bear of the Day article.

    Kinjel Shah headshot

    Pharma Stock Roundup: PFE to Buy RSV Drugmaker, FDA Updates for NVS, MRK and RHHBY

    by Kinjel Shah

    Pfizer (PFE) announces plans to acquire ReViral for up to $525 million. Merck (MRK), Novartis (NVS) and Roche (RHHBY) provide FDA updates.